FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2345763513> ?p ?o ?g. }

• W2345763513 endingPage "e3330" @default.
• W2345763513 startingPage "e3330" @default.
• W2345763513 abstract "In the management of patients with advanced-stage pure endometrioid-type endometrial cancer (E-EC), such as positive lymph nodes (stage III) or stage IV, treatment options are severely limited. This article aims to investigate the outcome of women with FIGO III-IV E-EC (based on FIGO 2009 system). The retrospective cohort study, based on the Taiwanese Gynecologic Oncology Group (TGOG-2005), enrolled patients undergoing staging surgery to have a pathologically confirmed FIGO III-IV E-EC from 22-member hospitals between 1991 and 2010. This cohort included 541 patients (stage III, n = 464; stage IV, n = 77). Five-year overall survival (OS) was 70.4%. Median progression-free survival (PFS) was 43 months (range 0–258 months) and median OS was 52 months (range 1–258 months). Multivariate analysis showed that FIGO stage, >1/2 myometrial invasion (hazard ratio [HR] 1.53, 95% confidence interval [CI] 1.12–2.09; P = 0.007), histological grade 3 (HR 2.0, 95% CI 1.47–2.75; P < 0.001), and metastases of pelvic and para-aortic lymph nodes (PLN and PALN) (HR 2.75, 95% CI 1.13–6.72; P < 0.001) were independent risk factors for PFS. FIGO stage, >1/2 myometrial invasion (HR 1.89, 95% CI 1.34–2.64; P < 0.001), and histological grade 3 (HR 2.42, 95% CI 1.75–3.35; P < 0.001) influenced OS. Complete dissection of PLN and PALN (HR 0.27, 95% CI 0.16–0.45; P < 0.001, and HR 0.14, 95% CI 0.08–0.26; P < 0.001) and the following paclitaxel-based therapy (HR 0.61, 95% CI 0.79–0.92; P = 0.017, and HR 0.48; 95% CI 0.31–0.75; P = 0.001) provided the better PFS and OS, respectively. In management of women with FIGO III-V E-EC, combination of complete staging surgery (complete dissection of PLN and PALN is included) and the following paclitaxel-based therapy could provide the better chance to survive. Patients with tumor >1/2 myometrial invasion and histological grade 3 are risky for disease-related mortality." @default.
• W2345763513 created "2016-06-24" @default.
• W2345763513 creator A5000225204 @default.
• W2345763513 creator A5001790190 @default.
• W2345763513 creator A5003303543 @default.
• W2345763513 creator A5003879226 @default.
• W2345763513 creator A5005791727 @default.
• W2345763513 creator A5006814648 @default.
• W2345763513 creator A5015489678 @default.
• W2345763513 creator A5028791665 @default.
• W2345763513 creator A5037055730 @default.
• W2345763513 creator A5063885219 @default.
• W2345763513 creator A5066406990 @default.
• W2345763513 creator A5076626440 @default.
• W2345763513 creator A5082178195 @default.
• W2345763513 creator A5090940398 @default.
• W2345763513 creator A5091155437 @default.
• W2345763513 date "2016-04-01" @default.
• W2345763513 modified "2023-10-16" @default.
• W2345763513 title "Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer" @default.
• W2345763513 cites W1510348669 @default.
• W2345763513 cites W1546838085 @default.
• W2345763513 cites W1970140589 @default.
• W2345763513 cites W1971310926 @default.
• W2345763513 cites W1974445472 @default.
• W2345763513 cites W1978542231 @default.
• W2345763513 cites W1979948006 @default.
• W2345763513 cites W1983928868 @default.
• W2345763513 cites W1998466115 @default.
• W2345763513 cites W2001966656 @default.
• W2345763513 cites W2010616025 @default.
• W2345763513 cites W2018812942 @default.
• W2345763513 cites W2038011108 @default.
• W2345763513 cites W2052957067 @default.
• W2345763513 cites W2061698426 @default.
• W2345763513 cites W2077294143 @default.
• W2345763513 cites W2078665951 @default.
• W2345763513 cites W2088959602 @default.
• W2345763513 cites W2098960933 @default.
• W2345763513 cites W2111467397 @default.
• W2345763513 cites W2111791117 @default.
• W2345763513 cites W2114519328 @default.
• W2345763513 cites W2115495448 @default.
• W2345763513 cites W2123879605 @default.
• W2345763513 cites W2136076925 @default.
• W2345763513 cites W2149243136 @default.
• W2345763513 cites W2159307123 @default.
• W2345763513 cites W2236460895 @default.
• W2345763513 cites W2274293361 @default.
• W2345763513 cites W2279056171 @default.
• W2345763513 cites W2317144453 @default.
• W2345763513 cites W2326917871 @default.
• W2345763513 cites W2329517822 @default.
• W2345763513 cites W2334784923 @default.
• W2345763513 cites W2909087835 @default.
• W2345763513 doi "https://doi.org/10.1097/md.0000000000003330" @default.
• W2345763513 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4839827" @default.
• W2345763513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27082583" @default.
• W2345763513 hasPublicationYear "2016" @default.
• W2345763513 type Work @default.
• W2345763513 sameAs 2345763513 @default.
• W2345763513 citedByCount "16" @default.
• W2345763513 countsByYear W23457635132016 @default.
• W2345763513 countsByYear W23457635132017 @default.
• W2345763513 countsByYear W23457635132018 @default.
• W2345763513 countsByYear W23457635132019 @default.
• W2345763513 countsByYear W23457635132020 @default.
• W2345763513 countsByYear W23457635132021 @default.
• W2345763513 countsByYear W23457635132022 @default.
• W2345763513 crossrefType "journal-article" @default.
• W2345763513 hasAuthorship W2345763513A5000225204 @default.
• W2345763513 hasAuthorship W2345763513A5001790190 @default.
• W2345763513 hasAuthorship W2345763513A5003303543 @default.
• W2345763513 hasAuthorship W2345763513A5003879226 @default.
• W2345763513 hasAuthorship W2345763513A5005791727 @default.
• W2345763513 hasAuthorship W2345763513A5006814648 @default.
• W2345763513 hasAuthorship W2345763513A5015489678 @default.
• W2345763513 hasAuthorship W2345763513A5028791665 @default.
• W2345763513 hasAuthorship W2345763513A5037055730 @default.
• W2345763513 hasAuthorship W2345763513A5063885219 @default.
• W2345763513 hasAuthorship W2345763513A5066406990 @default.
• W2345763513 hasAuthorship W2345763513A5076626440 @default.
• W2345763513 hasAuthorship W2345763513A5082178195 @default.
• W2345763513 hasAuthorship W2345763513A5090940398 @default.
• W2345763513 hasAuthorship W2345763513A5091155437 @default.
• W2345763513 hasBestOaLocation W23457635131 @default.
• W2345763513 hasConcept C121608353 @default.
• W2345763513 hasConcept C126322002 @default.
• W2345763513 hasConcept C126894567 @default.
• W2345763513 hasConcept C146357865 @default.
• W2345763513 hasConcept C151730666 @default.
• W2345763513 hasConcept C167135981 @default.
• W2345763513 hasConcept C207103383 @default.
• W2345763513 hasConcept C2777088508 @default.
• W2345763513 hasConcept C29456083 @default.
• W2345763513 hasConcept C44249647 @default.
• W2345763513 hasConcept C71924100 @default.
• W2345763513 hasConcept C86803240 @default.

• next